Want to see HK:0874 full AI Analyst Report?
Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(0874)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$13.50
â–¼(-10.42% Downside)
Action:Reiterated
Date:10/29/26
The score is primarily held back by weakening profitability and inconsistent cash conversion despite strong TTM revenue growth, alongside a clearly bearish technical trend (below major moving averages with weak momentum). These risks are partially offset by a reasonable P/E and a high dividend yield, which improve the overall attractiveness on valuation.
Positive Factors
Revenue Growth
Strong 28% TTM revenue growth indicates that the company is expanding its sales base across pharmaceutical and healthcare activities. If sustained, this growth can improve operating scale, support reinvestment in products and distribution, and reinforce its position across hospital and consumer channels.
Negative Factors
Margin Compression
The decline in net margin shows that revenue growth is not translating proportionally into earnings. Continued compression in net, EBITDA and operating margins could limit internal funding, reduce the benefit of scale, and make future profitability more dependent on product mix and cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong 28% TTM revenue growth indicates that the company is expanding its sales base across pharmaceutical and healthcare activities. If sustained, this growth can improve operating scale, support reinvestment in products and distribution, and reinforce its position across hospital and consumer channels.
Read all positive factors
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$35.15B
Dividend Yield6.68%
Average Volume (3M)968.07K
Price to Earnings (P/E)12.4
Beta (1Y)0.51
Revenue Growth6.00%
EPS Growth-23.05%
CountryHK
Employees27,057
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)1.33
Shares Outstanding219,900,000
10 Day Avg. Volume1,027,820
30 Day Avg. Volume968,072
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)0.68
Price to Sales (P/S)0.33
P/FCF Ratio-27.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.70Price Target Upside37.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.71
Revenue Forecast (FY)HK$78.45B
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditi...
How the Company Makes Money
The company makes money primarily by selling pharmaceutical and healthcare products through two major revenue engines: (1) pharmaceutical manufacturing and (2) pharmaceutical distribution.
1) Pharmaceutical manufacturing (product sales)
- Revenue...
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.81B | 77.66B | 74.99B | 75.52B | 70.79B | 69.01B |
| Gross Profit | 11.54B | 12.52B | 12.52B | 14.19B | 13.28B | 13.23B |
| EBITDA | 3.11B | 3.95B | 4.90B | 6.49B | 6.22B | 5.82B |
| Net Income | 2.17B | 2.98B | 2.84B | 4.06B | 3.97B | 3.72B |
Balance Sheet | ||||||
| Total Assets | 87.17B | 84.55B | 81.68B | 78.59B | 74.67B | 66.12B |
| Cash, Cash Equivalents and Short-Term Investments | 11.90B | 23.81B | 22.72B | 21.31B | 22.56B | 22.38B |
| Total Debt | 23.24B | 20.70B | 12.37B | 11.70B | 11.43B | 9.92B |
| Total Liabilities | 45.80B | 43.40B | 43.91B | 41.91B | 41.03B | 34.79B |
| Stockholders Equity | 39.01B | 37.80B | 35.90B | 34.92B | 32.07B | 29.06B |
Cash Flow | ||||||
| Free Cash Flow | 1.39B | -954.34M | 2.31B | 2.48B | 5.62B | 4.42B |
| Operating Cash Flow | 2.48B | 253.50M | 3.44B | 4.10B | 7.00B | 5.67B |
| Investing Cash Flow | -4.84B | -3.81B | -5.96B | -3.11B | -7.25B | -931.57M |
| Financing Cash Flow | 1.02B | -98.13M | -1.01B | -1.98B | 45.95M | -1.49B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Negative
15.07
Price Trends
13.40
Negative
14.14
Negative
15.43
Negative
Market Momentum
-0.12
Negative
40.98
Neutral
35.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0874, the sentiment is Negative. The current price of 15.07 is above the 20-day moving average (MA) of 13.11, above the 50-day MA of 13.40, and below the 200-day MA of 15.43, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 40.98 is Neutral, neither overbought nor oversold. The STOCH value of 35.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0874.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$25.88B | 15.90 | 11.32% | 7.05% | -9.56% | -23.22% | |
68 Neutral | HK$28.59B | 6.07 | 7.92% | 5.27% | 7.94% | 52.83% | |
61 Neutral | HK$24.03B | 13.50 | 8.60% | 3.49% | 14.80% | -2.88% | |
59 Neutral | HK$66.46B | 17.30 | 7.14% | 2.72% | 9.88% | 9.30% | |
58 Neutral | HK$15.42B | 13.56 | 6.61% | 3.89% | 7.35% | -45.49% | |
57 Neutral | HK$35.15B | 12.36 | 6.64% | 6.68% | 6.00% | -23.05% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
12.91
-4.07
-23.95%
HK:0867
China Medical System Holdings
9.85
-3.02
-23.47%
HK:1513
Livzon Pharmaceutical Group
22.08
-5.38
-19.58%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.55
-5.84
-26.08%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.55
-0.18
-3.87%
HK:0512
Grand Pharmaceutical Group Limited
4.35
-3.51
-44.70%
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Baiyunshan Pharmaceutical Sees Profit Slump Despite Steady Revenue in Q3 2026
Oct 28, 2026
Guangzhou Baiyunshan Pharmaceutical reported modest growth in operating income for the third quarter of 2026, with revenue up slightly year-on-year and total assets and shareholder equity increasing by just over 3%. However, profitability deterior...
Guangzhou Baiyunshan Sets Board Meeting to Approve Nine-Month Results
Oct 13, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for 28 October 2026 to review and approve the unaudited financial results for the nine months ended 30 September 2026. The session may also address addition...
Guangzhou Baiyunshan Affirms Compliance on Related Party Disclosures in 2025 Report
Sep 10, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited issued a supplemental announcement to its annual report for the year ended 31 December 2025, clarifying its handling of related party transactions under Hong Kong listing rules. The comp...
Baiyunshan Shareholders Approve All Resolutions at 2026 Extraordinary Meeting
Aug 28, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited held its first extraordinary general meeting of 2026 on 28 August in Guangzhou, with the session convened and chaired by board chairperson Chen Jiehui. The meeting complied with PRC comp...
Baiyunshan’s GP Corp Aggregates Receivables Sales Into Disclosable HKEX Deal
Aug 28, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company disclosed that its subsidiary GP Corp. has transferred a new batch of accounts receivable to Industrial Securities Asset Management for RMB146.32 million under an existing asset sale framework. ...
Baiyunshan Pharma Sets Mid-2026 Dividend in Unaudited Interim Report
Aug 21, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings has released a summary of its unaudited interim report for the six months ended 30 June 2026, prepared under China Accounting Standards for Business Enterprises. The board confirmed collective responsib...
Guangzhou Baiyunshan Declares 2026 Interim Dividend and Sets H Share Record Date
Aug 21, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings has declared a 2026 interim cash dividend of RMB0.30 per share for the six months ended 30 June 2026, following shareholder authorization at its 2025 AGM. The company will close its H share register fro...
Guangzhou Baiyunshan Pharma Announces 2026 Interim Dividend and Tax Treatment Details
Aug 21, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has declared an interim ordinary dividend of RMB 0.3 per share for the six months ended 30 June 2026, payable in Hong Kong dollars at HKD 0.3468 per share. The dividend relates to the fi...
Guangzhou Baiyunshan Schedules Board Meeting to Review 2026 Interim Results
Aug 10, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for 21 August 2026 to review and approve the unaudited financial results for the six months ended 30 June 2026. The meeting will also address any other busi...
Guangzhou Baiyunshan Pharma Calls August 2026 EGM to Vote on Board Pay
Aug 7, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company has called its first extraordinary general meeting of 2026 for 28 August in Guangzhou, convened by the board and open to H share investors recorded on the register that day. The company has set ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.